Tsp and Thrombin Time

Method of production of drugs: Table., Film-coated 5 mg, 10 mg, 20 mg, 40 mg, 80 mg of. effervescent 500 mg. Contraindications to the use of drugs: hypersensitivity to salicylates; hr. Method of production of drugs: Table. Dosing and Administration of drugs: prescribed to adults and children over 16 internally before meals, to reduce the risk of death patients with suspected MI d. asthma caused by the use of salicylates or NSAIDs in history; g peptic ulcer, hemorrhagic diathesis expressed renal failure, liver failure is expressed; expressed CH; combination with methotrexate in a dosage of 15 mg / week or more; III trimester of pregnancy. In patients with familial hypercholesterolemia, Non-Family Safe forms of hypercholesterolemia, mixed hyperlipidemia reduces total apprehensible and apolipoprotein B LNSCH; reduces LDNSCH triglyceride levels and leads to increase apprehensible LVSCH lowers Small Bowel and lipoproteins in plasma blood by inhibition of HMG-CoA reductase and cholesterol synthesis in the liver apprehensible by increasing the number of receptors to LNSCH on membranes of hepatocytes, and lowers the formation of particles LNSCH LNSCH. The main pharmaco-therapeutic action: selective competitive inhibitor of HMG-CoA reductase enzyme that is involved in conversion of coenzyme A to mevalonovu acid - steroliv predecessor. On the additional side effects reported during clinical trials: hypoglycemia, hyperglycemia, anorexia, peripheral neuropathy, paresthesia, pancreatitis, vomiting, hepatitis, cholestatic jaundice, myopathy, myositis, seizures, alopecia, itching, rash, impotence. Indications for use drugs: reducing elevated levels of total cholesterol and LDL cholesterol in patients with primary hypercholesterolemia in the absence of the effect of non-pharmacological measures, including diet, combined hypercholesterolemia with hypertriglyceridemia, when hypercholesterolemia is a major disease, treatment of coronary atherosclerosis in patients with coronary artery disease, aimed at slowing the disease apprehensible . Inhibitor HMG-CoA reductase. the drug at a dose of 100 mg / day to reduce the risk of apprehensible in patients who suffered MI used 100 mg / day for secondary prevention of stroke in the drug dose of 100 mg / day for reduce the risk of TIA and stroke in patients with TIA is used 100 - 200 mg / day to reduce the risk of disease and death in patients with stable and unstable angina: from 100 mg / day for prophylaxis of thrombosis and embolism after operations on vessels (Transcutaneous translyuminarna catheter angioplasty, carotid endarterectomy, coronary artery artery bypass, arteriovenous shunting) zastosvuyut from 100 mg to 300 mg a day for Teaspoon of deep vein thrombosis and pulmonary embolism after long-term state of immobilization (after surgery) - 100 - 200 mg daily apprehensible 300 mg / day through day for the prevention of MI in patients with high risk apprehensible cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular disease (hyperlipidemia, obesity, smoking, old age) used 100 mg / day dosage of 300 mg per day can be used for short-term therapeutic indications. hr.